News stories about Celsion Corporation (NASDAQ:CLSN) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Celsion Corporation earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.3615456486011 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Celsion Corporation (CLSN) traded up 0.74% during trading on Thursday, hitting $1.37. 31,255 shares of the stock were exchanged. The firm’s market cap is $11.44 million. The stock’s 50-day moving average price is $1.44 and its 200-day moving average price is $1.15. Celsion Corporation has a 12-month low of $0.19 and a 12-month high of $4.96.

A number of analysts recently commented on CLSN shares. Zacks Investment Research raised shares of Celsion Corporation from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a report on Tuesday, August 29th. ValuEngine raised shares of Celsion Corporation from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Maxim Group reissued a “hold” rating on shares of Celsion Corporation in a report on Thursday, June 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. Celsion Corporation presently has a consensus rating of “Hold” and a consensus price target of $24.88.

TRADEMARK VIOLATION NOTICE: This article was first published by Daily Political and is owned by of Daily Political. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at

Celsion Corporation Company Profile

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Insider Buying and Selling by Quarter for Celsion Corporation (NASDAQ:CLSN)

Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with's FREE daily email newsletter.